FrancophonIA/ELRC3.0 huggingface dataset:
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be co-administered with products containing efavirenz unless needed for dose adjustment e.g. with rifampicin (see section 4.2).
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije istodobno primjenjivati s lijekovima koji sadrže efavirenz, osim kada je to potrebno zbog prilagodbe doze, npr. s rifampicinom (vidjeti dio 4.2).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka film-coated tablets (tablets) are light orange pink, oval, biconvex, film-coated tablets with bevelled edges.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka filmom obložene tablete (tablete) su svijetlonarančastoružičaste, ovalne, bikonveksne filmom obložene tablete ukošenih rubova.
English: AUC: ↓ 26% (↓ 15 to ↓ 36) Cmax: ↓ 20% (↓ 11 to ↓ 28) Cmin: ↓ 32% (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Croatian: AUC: ↓ 26% (↓ 15 do ↓ 36) Cmax: ↓ 20% (↓ 11 do ↓ 28) Cmin: ↓ 32% (↓ 15 do ↓ 46) (indukcije CYP3A4 i CYP2B6)
English: Therefore co-administration of atazanavir/ritonavir and Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended (see Table 1).
Croatian: Iz tog se razloga ne preporučuje istodobna primjena atazanavira/ritonavira i lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (vidjeti Tablicu 1).
English: Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Croatian: Ne preporučuje se istodobna primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i didanozina jer se izloženost didanozinu značajno povećava u slučaju istodobne primjene tenofovirdizoproksila, što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
English: The pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil after co-administration of the separate pharmaceutical forms or as efavirenz/emtricitabine/tenofovir disoproxil have not been studied in HIV infected patients with renal impairment.
Croatian: Farmakokinetika efavirenza, emtricitabina i tenofovirdizoproksila nakon njihove istodobne primjene kao zasebnih farmaceutskih oblika ili davanja u obliku efavirenza/emtricitabina/tenofovirdizoproksila nije ispitivana u bolesnika inficiranim virusom HIV-a s oštećenjem funkcije bubrega.
English: Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week in combination with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Croatian: U režimima gdje se rifabutin daje 2 ili 3 puta tjedno u kombinaciji s lijekom Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka treba razmotriti udvostručavanje doze rifabutina.
English: Only a limited number of patients were co-infected with HBV (n = 13) or HCV (n = 26) in study GS01-934.
Croatian: Bolesnici istodobno inficirani HIV/HBV-om ili HCV-om U ispitivanju GS-01-934 samo je ograničeni broj bolesnika bio istodobno zaražen HBV-om (n=13) ili HCV-om (n=26).
English: Concomitant administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is expected to decrease plasma concentrations of velpatasvir and voxilaprevir.
Croatian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka i sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/ voksilaprevira smanjiti koncentraciju velpatasvira i voksilaprevira u plazmi.
English: If the patient vomits within 1 hour of taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, another tablet should be taken.
Croatian: U slučaju da bolesnik povraća unutar 1 sata od uzimanja lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, treba uzeti još jednu tabletu.
English: Use of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should be avoided with concurrent or recent use of a nephrotoxic medicinal product.
Croatian: Treba izbjegavati primjenu lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka istodobno s primjenom ili nakon nedavne primjene nefrotoksičnog lijeka.
English: Each film-coated tablet contains 600 mg of efavirenz (efavirenzum), 200 mg of emtricitabine (emtricitabinum) and 245 mg of tenofovir disoproxil (tenofovirum disoproxilum) (as succinate).
Croatian: Jedna filmom obložena tableta sadrži 600 mg efavirenza (efavirenzum), 200 mg emtricitabina (emtricitabinum) i 245 mg tenofovirdizoproksila (tenofovirum disoproxilum) (u obliku sukcinata).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka film-coated tablets are light orange pink, oval, biconvex, film-coated tablets with beveled edges.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka filmom obložene tablete su svijetlonarančastoružičaste, ovalne, bikonveksne filmom obložene tablete ukošenih rubova.
English: As a fixed combination, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other medicinal products containing the same active components, emtricitabine or tenofovir disoproxil.
Croatian: Kao lijek s fiksnom kombinacijom doza, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije primjenjivati istodobno s drugim lijekovima koji sadrže te iste komponente, emtricitabin ili tenofovirdizoproksil.
English: The following side effects are rare (these may affect up to 1 in every 1,000 patients)
Croatian: Sljedeće nuspojave su rijetke (mogu se pojaviti u do 1 na svakih 1000 bolesnika)
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is a fixeddose Combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka must not be coadministered.
Croatian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka lijek s fiksnom kombinacijom doza, doza efavirenza se ne može mijenjati, što znači da se vorikonazol i Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka ne smiju primjenjivati istodobno.
English: Darunavir/ritonavir/Emtricitabine Interaction not studied.
Croatian: Cmin: ↑ 37% darunavir/ritonavir/emtricitabin Interakcija nije ispitana.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka je kombinacija fiksne doze efavirenza, emtricitabina i tenofovirdizoproksila.
English: Refer to the Summary of Product Characteristics for elbasvir/grazoprevir for more information.
Croatian: sažetke opisa svojstava lijeka za elbasvir/grazoprevir.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended if you have moderate to severe kidney disease.
Croatian: Uzimanje lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ne preporučuje se ako imate umjerenu ili tešku bolest bubrega.
English: It is recommended that Efavirenz/Emtricitabine/Tenofovir disoproxil Krka be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Croatian: Preporučuje se uzimanje efavirenza/emtricitabina/tenofovirdizoproksila na prazan želudac jer hrana može povećati izloženost efavirenzu i može dovesti do povećane učestalosti nuspojava (vidjeti dijelove 4.4 i 4.8).
English: M184V/I K65R K70E TAMs
Croatian: M184V/I
English: AUC: ↔*/** (↓ 10% to ↑ 26%) Cmax: ↔*/** (↓ 5% to ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 to ↑ 49) (CYP3A4 induction).
Croatian: AUC: ↔*/** (↓ 10% do ↑ 26%) Cmax: ↔*/** (↓ 5% do ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 do ↑ 49) (indukcija CYP3A4). * U usporedbi s atazanavirom 300 mg/ritonavirom 100 mg q.d. koji se uzima navečer, bez efavirenza.
English: The administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in frequency of adverse reactions (see section 4.8).
Croatian: Uzimanje lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka s hranom može povećati izloženost efavirenzu (vidjeti dio 5.2) te može dovesti do povećane učestalosti nuspojava (vidjeti dio 4.8).
English: If
Croatian: Ako se
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of itraconazole or posaconazole in your blood.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka može smanjiti količinu itrakonazola ili posakonazola u krvi.
English: Lopinavir/ritonavir/Tenofovir disoproxil (400 mg b.i.d./100 mg b.i.d./245 mg q.d.)
Croatian: lopinavir/ritonavir/tenofovirdizopro ksil (400 mg b.i.d./100 mg b.i.d./245 mg q.d.)
English: maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)
Croatian: Često pruritus vezikulobulozni osip, pustulozni osip, makulopapulozni osip, osip, pruritus, urtikarija, promjena boje kože (pojačana pigmentacija)
English: The administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 5.2).
Croatian: Primjenjivanje lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka s hranom može povećati izloženost efavirenzu te može dovesti do povećane učestalosti nuspojava (vidjeti dijelove 4.4 i 5.2).
English: This loss is due to significant decreases in elbasvir/grazoprevir plasma concentrations caused by CYP3A4 or P-gp induction.
Croatian: Taj učinak posljedica je značajnih smanjenja koncentracija elbasvira/grazoprevira u plazmi zbog indukcije CYP3A4 ili P-gpa. za više informacija pogledajte efavirenz: AUC: ↔ Cmax: ↔
English: Since use of two NNRTIs proved not beneficial in terms of efficacy and safety, co-administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and another NNRTI is not recommended.
Croatian: Budući da se korištenje dvaju lijekova klase NNRTI nije pokazalo korisnim u smislu djelotvornosti i sigurnosti, ne preporučuje se istodobna primjena lijeka
English: Do not breast-feed during treatment with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Nemojte dojiti tijekom liječenja lijekom Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Ethinyloestradiol: AUC: ↔ Cmax: ↔
Croatian: etinilestradiol: AUC: ↔ Cmax: ↔
English: Values for Test and Reference are mean (% coefficient of variation).
Croatian: Vrijednosti za test i referencu su srednje vrijednosti (% koeficijenta varijabilnosti) GMR=omjer geometrijskih srednjih vrijednosti najmanjih kvadrata, IP=interval pouzdanosti
English: No dose adjustment of rifampicin is recommended when given with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Croatian: Ne preporučuje se prilagođavanje doze rifamipicina kada se primjenjuje s lijekom Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of the anticonvulsant in your blood.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka može smanjiti koncentraciju antikonvulziva u krvi.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg film-coated tablets
Croatian: Efavirenz/Emtricitabine/Tenofovirdisoproxil Krka 600 mg/200 mg/245 mg filmom obložene tablete
English: Co-administration of ritonavir at doses of 600 mg and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is not recommended.
Croatian: Ne preporučuje se istodobna primjena ritonavira u dozama od 600 mg s lijekom Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is coadministered with an anticonvulsant that is a substrate of CYP isozymes, periodic monitoring of anticonvulsant levels should be conducted.
Croatian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka primjenjuje istodobno s antikonvulzivom koji je supstrat CYP izozima,
English: Concomitant administration of atovaquone/proguanil with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be avoided.
Croatian: Istodobnu primjenu atovakona/progvanila s lijekom Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka treba izbjegavati.
English: Protease inhibitors Atazanavir/ritonavir/Tenofovir disoproxil (300 mg q.d./100 mg q.d./245 mg q.d.)
Croatian: Antivirusni lijekovi protiv HIV-a Inhibitori proteaze atazanavir/ritonavir/tenofovirdizopr oksil (300 mg q.d./100 mg q.d./245 mg q.d.)
English: Uncommon anaemia
Croatian: Manje često anemija
English: Co-administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka with sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is not recommended (see section 4.4).
Croatian: Ne preporučuje se istodobna primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilaprevira (vidjeti dio 4.4 i Tablicu 1).
English: The adverse reactions from clinical study and post-marketing experience with efavirenz/emtricitabine/tenofovir disoproxil and the individual components of efavirenz/emtricitabine/tenofovir disoproxil in antiretroviral combination therapy are listed in Table 2 below by body system organ class, frequency and the component(s) of efavirenz/emtricitabine/tenofovir disoproxil to which the adverse reactions are attributable.
Croatian: Nuspojave iz kliničkih ispitivanja i iskustva nakon stavljanja lijeka u promet s efavirenzom/emtricitabinom/tenofovirdizoproksilom i pojedinačnim komponentama efavirenza/emtricitabina/tenofovirdizoproksila u kombiniranoj antiretrovirusnoj terapiji navedene su u
English: Each film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as succinate).
Croatian: Jedna filmom obložena tableta sadrži 600 mg efavirenza, 200 mg emtricitabina i 245 mg of tenofovirdizoproksila (u obliku sukcinata).
English: Methadone/Efavirenz (35-100 mg q.d./600 mg q.d.)
Croatian: OPIOIDI metadon/efavirenz (35-100 mg q.d./600 mg q.d.)
English: The pharmacokinetics of efavirenz/emtricitabine/tenofovir disoproxil have not been studied in HIV infected patients with hepatic impairment.
Croatian: Farmakokinetika lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka nije ispitana u bolesnika s oštećenjem funkcije jetre.
English: What Efavirenz/Emtricitabine/Tenofovir disoproxil Krka looks like and contents of the pack
Croatian: Kao Efavirenz/Emtricitabine/Tenofovir disoproxil Krka izgleda i sadržaj pakiranja
English: Efavirenz/emtricitabine/tenofovir disoproxil should be administered with caution to patients with mild hepatic impairment (see sections 4.3 and 4.4).
Croatian: Potrebna je pažnja u slučaju davanja efavirenza/emtricitabina/tenofovirdizoproksila bolesnicima s blagim oštećenjem funkcije jetre (vidjeti dijelove 4.3 i 4.4).
English: When co-administered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, sertraline dose increases should be guided by clinical response.
Croatian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, povećanja doze sertralina treba usklađivati s kliničkim odgovorom.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should be administered with caution to elderly patients (see section 4.4).
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se starijim osobama treba davati uz oprez (vidjeti dio 4.4).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can be reinitiated in patients interrupting therapy because of rash.
Croatian: Može se ponovo započeti s davanjem lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bolesnicima u kojih je terapija prekinuta zbog osipa.
English: Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5) while on therapy with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Tijekom terapije lijekom Efavirenz/Emtricitabine/Tenofovir disoproxil Krka barijerna kontracepcija se uvijek treba koristiti u kombinaciji s drugim metodama kontracepcije (na primjer, oralnim ili drugim hormonalnim kontraceptivima, vidjeti dio 4.5).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg film-coated tablets efavirenz/emtricitabine/tenofovir disoproxil
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg filmom obložene tablete efavirenzum/emtricitabinum/tenofovirum disoproxilum
English: No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve patients or in heavily pretreated patients.
Croatian: Trenutno nema dostupnih podataka iz kliničkih ispitivanja s efavirenzom/emtricitabinom/tenofovirdizoproksilom na bolesnicima koji nisu bili prethodno liječeni, kao ni na onima sa značajnim prethodnim liječenjima.
English: If you stop taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Croatian: Ako prestanete uzimati Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
English: These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particulary neurologic findings, These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.
Croatian: Te nalaze treba uzeti u obzir u svakog djeteta koje je in utero bilo izloženo analozima nukleozida i nukleotida, a koje je imalo tešku kliničku sliku nepoznate etiologije, osobito neurološke nalaze.
English: Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and St. John's wort or herbal preparations containing St. John's wort is contraindicated.
Croatian: Istodobna primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i gospine trave ili biljnih pripravaka koji sadržavaju gospinu travu je kontraindicirana.
English: Gastrointestinal disorders: Very common diarrhoea, nausea diarrhoea,
Croatian: Poremećaji probavnog sustava: Vrlo često proljev, mučnina proljev, povraćanje, mučnina
English: Patients with moderate or severe renal impairment require a dose adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Croatian: U bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega nužno je prilagođavanje doziranja emtricitabina i tenofovirdizoproksila, što se ne može postići kombiniranom tabletom (vidjeti dijelove 4.2 i 5.2).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may affect your kidneys.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka može negativno utjecati na bubrege.
English: particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Croatian: Može biti indiciran nadzor funkcije bubrega, osobito u bolesnika s postojećom sistemskom bolešću ili bolešću bubrega te u bolesnika koji uzimaju nefrotoksične lijekove.
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and vigabatrin or gabapentin can be coadministered without dose adjustment.
Croatian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka i vigabatrin ili gabapentin mogu se primjenjivati istodobno bez prilgođavanja doze.
English: AUC0-last (ng∙h/ml) 125,623.6
Croatian: Cmax (ng/ml) 2264,3
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).
Croatian: U bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega nužno je prilagođavanje intervala doziranja emtricitabina i tenofovirdizoproksila što se ne može postići kombiniranom tabletom (vidjeti dijelove 4.4 i 5.2).
English: Valproic acid/Efavirenz (250 mg b.i.d./600 mg q.d.)
Croatian: valproična kiselina/efavirenz (250 mg b.i.d./600 mg q.d.)
English: Your doctor may then conduct blood tests at regular intervals in order to check how well your liver is working (see section 3, If you stop taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka).
Croatian: Vaša jetra radi (pogledajte dio 3, Ako prestanete uzimati Efavirenz/Emtricitabine/Tenofovir disoproxil Krka).
English: It is important not to miss a dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Važno je da ne propustite uzeti dozu lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Do not take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka:
Croatian: Nemojte uzimati Efavirenz/Emtricitabine/Tenofovir disoproxil Krka:
English: Women of childbearing potential should undergo pregnancy testing before initiation of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Žene reproduktivne dobi trebaju prije početka terapije lijekom Efavirenz/Emtricitabine/Tenofovir disoproxil Krka obaviti testiranje trudnoće.
English: Dosage adjustments of atorvastatin may be required when co-administered with
Croatian: Podešavanja doze diltiazema kada se primjenjuje istodobno s lijekom
English: Cmax: ↓ 37% (↓ 20 to ↓ 51) Cmin: ↓ 44% (↓ 27 to ↓ 58) (decrease in itraconazole concentrations: CYP3A4 induction)
Croatian: AUC: ↓ 39% (↓ 21 do ↓ 53) Cmax: ↓ 37% (↓ 20 do ↓ 51) Cmin: ↓ 44% (↓ 27 do ↓ 58) (smanjenje koncentracija itrakozanola: indukcija CYP3A4)
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 4.4).
Croatian: U bolesnika s umjerenim odnosno teškim oštećenjem funkcije bubrega nužno je prilagođavanje intervala doziranja emtricitabina i tenofovirdizoproksila, što se ne može postići kombiniranom tabletom (vidjeti dijelove 4.2 i 4.4).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended for patients with moderate or severe renal impairment (creatinine clearance (CrCl) < 50 ml/min).
Croatian: Ne preporučuje se davanje lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bolesnicima s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina (CrCl) < 50 ml/min).
English: You must not take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with certain medicines.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije uzimati zajedno s određenim lijekovima.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of statins in your blood.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka može smanjiti koncentraciju statina u krvi.
English: Fosamprenavir/ritonavir/Tenofovir disoproxil
Croatian: fosamprenavir/ritonavir/tenofovirdi zoproksil
English: Co-administration of efavirenz with atazanavir/ritonavir is not recommended.
Croatian: Ne preporučuje se istodobna primjena atazanavira/ritonavira s lijekom
English: Emtricitabine: AUC: ↔ Cmax: ↔
Croatian: emtricitabin: AUC: ↔ Cmax: ↔
English: ANTICONVULSANTS Carbamazepine/Efavirenz (400 mg q.d./600 mg q.d.)
Croatian: ANTIKONVULZIVI karbamazepin/efavirenz (400 mg q.d./600 mg q.d.)
English: Other medicines and Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Croatian: Drugi lijekovi i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
English: Since Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Efavirenz/Emtricitabine/Tenofovir disoproxil
Croatian: Budući da je Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lijek s kombinacijom fiksnih doza, doza efavirenza se ne može mijenjati, što znači da se vorikonazol i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ne smiju primjenjivati istodobno (vidjeti dio 4.3 i Tablicu 1).
English: Co-administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and didanosine is not recommended (see section
Croatian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka i didanozina (vidjeti dio 4.4).
English: Insufficient data are available to make a dosing recommendation for indinavir when dosed with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Croatian: Nije dostupno dovoljno podataka za određivanje preporuke doze za sakvinavir/ritonavir kada se primjenjuje s lijekom Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: EXPIRY DATE
Croatian: CYP izozima
English: Antifungals
Croatian: angioedem